Valiant Laboratories Stock Screener | Share Price & Fundamental Analysis
VALIANTLAB
Pharmaceuticals
Screen Valiant Laboratories share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹73.26
▲
2.80 (3.97%)
Share Price BSE
₹73.50
▲
2.19 (3.07%)
Market Cap
₹380.19 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.23
EPS (TTM)
₹-0.51
Dividend Yield
-
Debt to Equity
0.42
52W High
₹111.84
52W Low
₹64.57
Operating Margin
-
Profit Margin
-
Revenue (TTM)
₹47.00
EBITDA
₹1.00
Net Income
-
Total Assets
₹401.00
Total Equity
₹234.00
Valiant Laboratories Share Price History - Stock Screener Chart
Screen VALIANTLAB historical share price movements with interactive charts. Analyze price trends and patterns.
Valiant Laboratories Company Profile - Fundamental Screener
Screen Valiant Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for VALIANTLAB shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0JWS01017
Valiant Laboratories Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen VALIANTLAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 |
|---|---|---|---|
| Assets | |||
| Total Assets | 401 | 343 | 213 |
| Current Assets | 193 | 226 | 151 |
| Fixed Assets | 48 | 50 | 48 |
| Liabilities | |||
| Total Liabilities | 401 | 343 | 213 |
| Current Liabilities | 107 | 77 | 62 |
| Non-Current Liabilities | 0 | 0 | 0 |
| Shareholders' Equity | |||
| Total Equity | 234 | 237 | 101 |
| Share Capital | 44 | 44 | 33 |
| Reserves & Surplus | 191 | 193 | 68 |
Screen VALIANTLAB income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47 | 48 | 56 | 37 | 25 | 22 | 33 | 42 | 63 | 54 | 92 | 72 | 84 |
| Expenses | 46 | 44 | 54 | 35 | 28 | 21 | 35 | 47 | 61 | 48 | 81 | 61 | 79 |
| EBITDA | 1 | 3 | 2 | 2 | -3 | 0 | -2 | -5 | 2 | 6 | 10 | 11 | 4 |
| Operating Profit % | 0.00% | 5.00% | 7.00% | 2.00% | -31.00% | -13.00% | -15.00% | -16.00% | -2.00% | 7.00% | 10.00% | 14.00% | 5.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 3 | 1 | 2 | -4 | 0 | -3 | -5 | 1 | 6 | 10 | 10 | 4 |
| Tax | 0 | 1 | 0 | -1 | 1 | 0 | -1 | -2 | 0 | 2 | 2 | 3 | 1 |
| Net Profit | 0 | 2 | 1 | 2 | -5 | -1 | -1 | -4 | 1 | 4 | 8 | 8 | 3 |
| EPS | 0.04 | 0.42 | 0.16 | 0.54 | -1.09 | -0.13 | -0.33 | -0.81 | 0.24 | 1.31 | 2.41 | 4.70 | 1.65 |
Valiant Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen VALIANTLAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March |
|---|---|---|---|
| Operating Activities | 1 | 2 | 56 |
| Investing Activities | -53 | -144 | -55 |
| Financing Activities | 45 | 152 | -1 |
| Net Cash Flow | -7 | 11 | 0 |
Screen VALIANTLAB shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Aug | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FII Holding | 0.64% | 0.63% | 0.52% | 0.02% | 3.48% | 1.89% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.46% | 0.00% | 0.00% | 0.03% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.28% | 17.05% | 17.08% | 18.19% | 15.16% | 16.09% | 17.30% | 17.55% |
| Other Holding | 8.13% | 6.92% | 7.46% | 6.85% | 6.39% | 7.07% | 7.76% | 7.51% |
| Shareholder Count | 15,036 | 14,432 | 14,948 | 15,075 | 14,914 | 14,249 | 15,189 | 15,692 |
Valiant Laboratories Dividend Screener - Share Yield Analysis
Screen VALIANTLAB dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Valiant Laboratories Index Membership - Market Screener Classification
Screen VALIANTLAB by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Valiant Laboratories Market Events Screener - Corporate Actions
Screen VALIANTLAB market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 1.55% | ||
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -1.09% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | 3.60% |
| 2025-07-18 | 2025-07-19 | Rights | 1:4 | -1.43% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 3.47% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | 6.48% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.59% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | -13.18% |
Valiant Laboratories Competitors Screener - Peer Comparison
Screen VALIANTLAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,614 | 39.35 | 54,729 | 9.71% | 10,980 | 38.94 |
| Divis Laboratories | 169,701 | 68.64 | 9,712 | 18.67% | 2,191 | 47.61 |
| Torrent Pharmaceuticals | 130,301 | 60.42 | 11,539 | 6.99% | 1,911 | 63.27 |
| Cipla | 122,079 | 22.17 | 28,410 | 7.12% | 5,291 | 50.85 |
| Dr Reddys Laboratories | 106,115 | 18.42 | 33,741 | 16.73% | 5,725 | 53.02 |
| Lupin | 96,362 | 21.87 | 22,910 | 13.74% | 3,306 | 57.47 |
| Zydus Life Science | 92,005 | 18.03 | 23,511 | 18.55% | 4,615 | 43.59 |
| Mankind Pharma | 90,673 | 50.11 | 12,744 | 20.90% | 2,007 | 49.10 |
| Aurobindo Pharma | 68,709 | 20.16 | 32,346 | 9.43% | 3,484 | 45.26 |
| Alkem Laboratories | 65,838 | 26.89 | 13,458 | 3.70% | 2,216 | 41.76 |
Valiant Laboratories Company Announcements - News Screener
Screen VALIANTLAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-02 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2026-01-02 | Closure of Trading Window | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Board Comments On The Communication Received From The Stock Exchanges | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2025-11-11 | Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-11 | Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended September 302025. | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-09-29 | Closure of Trading Window | View |
| 2025-09-26 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-25 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-25 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-01 | Letter To Shareholders | View |
| 2025-09-01 | Notice Of 4Th Annual General Meeting | View |
| 2025-09-01 | Reg. 34 (1) Annual Report. | View |